Easy access to products and protocols for research use only in the identification of 2019-nCoV based on Centers for Disease Control and Prevention (CDC) recommendations
So much has changed during this unprecedented time, except your ability to count on Avantor. We continue to set science in motion to create a better world by providing you with the right solutions to keep moving forward.
Our solutions, developed with you as our focus, are crafted by our team and network of professionals with advanced degrees in science, quality control, engineering, manufacturing and industry experience.
Avantor supports end-to-end fluid management solutions – including peristaltic pumps and aseptic fluid transfer solutions – that are reliable and customer-centric, helping bioprocessing manufacturers meet their research and production goals.
A strong, vibrant research and development group is the lifeblood of all industries. VWR will support you from the latest life science products to the guaranteed purity of organic building blocks...
VWR is ready to support your production facility with reliable access to raw materials and essential supplies. We can also help you increase productivity...
VWR is proud of our years of experience providing choice and excellent service to the Industrial market from Food & Beverage, Petrochemical, Environmental Testing, Waste Water, Cosmetics, Consumer Goods, Agriculture and more...
VWR is your complete source for workplace supplies. Binders, calendars, pens, cleaning and sanitation supplies, and office equipment are just some of the essential products we offer...
New Avantor® J.T.Baker® premium conductive and non-conductive robotic tips deliver superior quality and reliable performance for results you can trust.
Avantor Services provides a wide range of specialized services and digital solutions to help you solve complex challenges.
We’ve built our reputation on consistent, comprehensive mastery of day-to-day operations, allowing lab, clinical, and production environments to focus their high-value resources on core scientific priorities.
As our customers’ needs have evolved, so have our capabilities. We have become experts in scientific operations, improving performance with sophisticated solutions and providing guidance on best practices.
You can select and customize services for peak efficiency, quality, and accelerated innovation.
jetMESSENGER™ is a mRNA transfection reagent that has been specifically designed to offer outstanding transfection efficiency in cells that are usually hard to transfect, allowing relevant gene expression experiments in all cell types.
Unmatched transfection efficiency
High efficiency on a wide variety of difficult to transfect cells
Outperform DNA transfection by switching to mRNA
Extremely gentle on cells
No risk of genome integration
Perfectly suited for CRISPR/Cas9 gene editing, iPS generation, stem cell differentiation and immunotherapy assays
jetMESSENGER™ has been designed to transfect cells that are slow dividing or that have developed specific mechanisms such as primary cells, neurons, suspension cells and various cancer cell lines. jetMESSENGER™ is a highly efficient and gentle mRNA transfection reagent. mRNA transfection presents many advantages versus DNA transfection:
no risk of genome integration, hence no genome modification of the transfected cell
no promoter regulation issue
no need to reach the nucleus for efficient expression
more gentle process
jetMESSENGER™ has been specifically designed to offer outstanding transfection efficiency in cells that are usually hard to transfect, finally allowing relevant gene expression experiments in almost all cell types
jetMESSENGER™ outperforms its main DNA transfection reagent competitor. Transfection efficiency was assessed by FACS analysis in various cell lines 24 h after transfection of eGFP mRNA (5meC, pseudo-uridine, Trilink™) or plasmid DNA encoding for eGFP. Conditions were used according to the manufacturers’ recommendation.
With jetMESSENGER™, achieve outstanding transfection efficiency in a wide variety of cell lines, from adherent and suspension cancer cells, to sensitive primary cells and neurons. jetMESSENGER™ is also perfectly suitable for reprogramming experiments in fibroblasts and stem cells.
jetMESSENGER™ leads to high transfection efficiency in a wide variety of cell types.
By eliminating the need to reach the nucleus for efficient expression, jetMESSENGER™ allows transfection of quiescent and slow dividing cells. In addition, jetMESSENGER™ operates through an extremely gentle process. Cell viability remains extremely high during transfection and cell morphology is maintained. Make your transfection experiments physiologically relevant!
jetMESSENGER™ provides a better cell viability and a higher protein expression than DNA transfection. Primary Rat Cortical neurons, Hep G2 and mouse stem cells were analyzed 48 h after transfection using phase contrast and fluorescent microscopy. The transfections were performed with jetMESSENGER™/eGFP mRNA (5meC, pseudo-uridine, Trilink™) and L2K/eGFP plasmid DNA according to the manufacturers’ recommendations for each reagent.
Examples of citations
Viegas C.S.B., Costa R.M., Santos L., Videira P.A., Silva Z., Araújo N., Macedo A.L., Matos AP., Vermeer C., Simes D.C. (2017). Gla-rich protein function as an anti-inflammatory agent in monocytes/macrophages: Implications for calcification-related chronic inflammatory diseases. PLoS Ones, DOI:10.1371/journal.pone.0177829
Sultana N., Magadum A., Hadas Y., Kondrat J., Singh N., Youssef E., Calderon D., Chepurko E., Dubois N., Hajjar RJ., Zangi L. (2017). Optimizing Cardiac Delivery of Modified mRNA. Mol Ther, DOI:10.1016/j.ymthe.2017.03.016
Testimonials
"Application of jetMESSENGER reagent to introduce modified RNA molecules into primary lung mouse endothelial cells (a cell population which is generally hard to transfect with DNA/RNA using non-viral methodology) resulted with the highest transfection rate (>70%) and with the lowest toxicity effects as compared to other tested RNA/DNA transfection reagents (jetPEI, TransIT, & RNAiMAX)." Itkin T., Weill Cornell Medicine, New York, United States
